<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011920</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG32</org_study_id>
    <nct_id>NCT01011920</nct_id>
  </id_info>
  <brief_title>Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma</brief_title>
  <official_title>Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter open label randomized phase II trial.

      Enrolled Primary Central Nervous System Lymphoma (PCNSL) patients will be stratified
      according to the IELSG score and randomized to receive one of the follows as primary
      chemotherapy:

        -  Arm A: Methotrexate (MTX) + Cytarabine (Ara-C)

        -  Arm B: MTX + Ara-C + rituximab

        -  Arm C: MTX + Ara-C + rituximab + thiotepa.

      Chemotherapy will be administered every three weeks. The maximum number of chemotherapy
      induction courses will be 4. Patients in Stable Disease (SD) or better after two courses will
      receive two more courses of the same primary chemotherapy regimen. Stem-cells harvest will be
      performed in the three arms after the second course. After 4 courses response assessment will
      be performed.

      Patients who will not achieve SD or better after the 4th course, as well as those who will
      experience Progressive Disease (PD) at any time and those who will not achieve a sufficient
      stem cell harvest, will receive Whole Brain Radiation Therapy (WBRT) 36-40 Gy +/- tumor bed
      boost of 9 Gy.

      Patients who will achieve SD or better after the 4th course will be stratified according to
      objective response to primary chemotherapy and to primary chemotherapy regimen and randomly
      allocated to receive as consolidation therapy one of the follows:

        -  Arm D: WBRT 36 Gy +/- boost 9 Gy

        -  Arm E: Carmustine (BCNU) + Thiotepa + Autologous Peripheral Blood Stem Cell Transplant
           (APBSCT) Patients in Complete Response (CR) after WBRT or APBSCT will remain in
           follow-up. Patients who will not achieve a CR after WBRT will be managed according to
           physician's preferences. Patients who will not achieve a CR after APBSCT will be
           referred to WBRT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate after primary chemotherapy and 2 years failure free survival at second randomization</measure>
    <time_frame>3 months, 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety, as acute and long-term toxicity</measure>
    <time_frame>Throughout all the active treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From entry onto trial until death for any cause</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>MTX+ AraC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ara-C +Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B Rituximab 375 mg/m2 conventional infusion d -5 &amp; 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ara-C + rituximab+thiotepa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C Rituximab 375 mg/m2 conventional infusion d -5 &amp; 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBRT 36 Gy +/- boost 9 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCNU + Thiotepa + APBSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 &amp; -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.</description>
    <arm_group_label>MTX+ AraC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ara-C</intervention_name>
    <description>Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses</description>
    <arm_group_label>MTX+ AraC</arm_group_label>
    <arm_group_label>Ara-C +Rituximab</arm_group_label>
    <arm_group_label>Ara-C + rituximab+thiotepa</arm_group_label>
    <other_name>Cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m2 conventional infusion on day - 5 &amp; 0 every 3 weeks for a maximum of 4 cycles</description>
    <arm_group_label>Ara-C +Rituximab</arm_group_label>
    <arm_group_label>Ara-C + rituximab+thiotepa</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 &amp; -4</description>
    <arm_group_label>Ara-C + rituximab+thiotepa</arm_group_label>
    <arm_group_label>BCNU + Thiotepa + APBSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.</description>
    <arm_group_label>WBRT 36 Gy +/- boost 9 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCNU</intervention_name>
    <description>BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6</description>
    <arm_group_label>BCNU + Thiotepa + APBSCT</arm_group_label>
    <other_name>Carmustine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>APBSCT</intervention_name>
    <description>Autologous peripheral blood stem cell transplant (APBSCT)</description>
    <arm_group_label>BCNU + Thiotepa + APBSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological assessed diagnosis of non-Hodgkin's lymphoma.

          -  Diagnostic sample obtained by stereotactic or surgical biopsy, Cerebrospinal Fluid
             (CSF) cytology examination or vitrectomy.

          -  Disease exclusively localized into the central nervous system, CSF, cranial nerves or
             eyes.

          -  At least one measurable lesion.

          -  Previously untreated patients (previous or ongoing steroid therapy admitted).

          -  Age 18-65 years (with ECOG Performance Status 0-3) or 66-70 (with ECOG Performance
             Status 0-2).

          -  Adequate bone marrow, renal, cardiac, and hepatic function.

          -  Sexually active patients of childbearing potential agreeing in implementing adequate
             contraceptive measures during study participation.

          -  Absence of any familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule.

          -  Patient-signed informed consent obtained before registration.

        Exclusion Criteria:

          -  Patients with lymphomatous lesions outside the CNS.

          -  Patients with a previous non-Hodgkin lymphoma at any time.

          -  Previous or concurrent malignancies with the exception of surgically cured carcinoma
             in-situ of the cervix, carcinoma of the skin or other cancers without evidence of
             disease at least from 5 years.

          -  HBsAg and HCV positivity.

          -  HIV infection, previous organ transplantation or other clinically evident form of
             immunodeficiency.

          -  Concurrent treatment with other experimental drugs.

          -  Concurrent Pregnancy or lactation.

          -  Patients not agreeing to take adequate contraceptive measures during the study.

          -  Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication
             or myocardial infarction within the last 6 months (New York Heart Association Class
             III or IV heart disease).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés JM Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Raffaele H Scientific Institute, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald Illerhaus, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center, Freiburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emanuele Zucca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IOSI, Bellinzona, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Klinik für Hämatologie Universitätsklinikum Essen&quot;</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskrankenhaus Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich Schiller Universitaet Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität in München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele H Scientific Institute</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto I</name>
      <address>
        <city>Nocera Inferiore</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile S.Spirito</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi La Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore S. Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IOSI - Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>newly diagnosed primary central nervous system lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

